DENVER, June 24, 2021 (GLOBE NEWSWIRE) — Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, today announced that it has selected substance use disorder and smoking cessation as the initial…


Previous articleBook Review: Alexander Shulgin’s The Nature of Drugs
Next articleExclusively-Natural Psychedelic Pharma Company, Filament Health, Lists on the NEO Exchange